Premium
Comparison of survival outcome between donor types or stem cell sources for childhood acute myeloid leukemia after allogenic hematopoietic stem cell transplantation: A multicenter retrospective study of Study Alliance of Yeungnam Pediatric Hematology‐oncology
Author(s) -
Shim Ye Jee,
Lee Jae Min,
Kim Heung Sik,
Jung Nani,
Lim Young Tak,
Yang Eu Jeen,
Hah Jeong Ok,
Lee YoungHo,
Chueh Hee Won,
Lim Jae Young,
Park Eun Sil,
Park Jeong A,
Park Ji Kyoung,
Park Sang Kyu
Publication year - 2018
Publication title -
pediatric transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.457
H-Index - 69
eISSN - 1399-3046
pISSN - 1397-3142
DOI - 10.1111/petr.13249
Subject(s) - medicine , hematopoietic stem cell transplantation , stem cell , myeloid leukemia , umbilical cord , cord blood , transplantation , bone marrow , leukemia , haematopoiesis , retrospective cohort study , immunology , genetics , biology
We compared transplant outcomes between donor types and stem cell sources for childhood acute myeloid leukemia ( AML ). The medical records of children with AML in the Yeungnam region of Korea from January 2000 to June 2017 were reviewed. In all, 76 children with AML (male‐to‐female ratio = 46:30) received allogenic hematopoietic stem cell transplantation (allo‐ HSCT ). In total, 29 patients received HSCT from either a matched‐related donor or a mismatched‐related donor, 32 patients received an unrelated donor, and 15 patients received umbilical cord blood. In term of stem cell sources, bone marrow was used in 15 patients and peripheral blood in 46 patients. For all HSCT cases, the 5‐year overall survival ( OS ) was 73.1% (95% CI : 62.7‐83.5) and the 5‐year event‐free survival ( EFS ) was 66.1% (95% CI : 54.5‐77.7). There was no statistical difference in 5‐year OS according to the donor types or stem cell sources ( P = .869 and P = .911). There was no statistical difference in 5‐year EFS between donor types or stem cell sources ( P = .526 and P = .478). For all HSCT cases, the 5‐year relapse rate was 16.1% (95% CI : 7.3‐24.9) and the 5‐year non‐relapse mortality ( NRM ) was 13.3% (95% CI : 5.1‐21.5). There was no statistical difference in the 5‐year relapse rate according to the donor types or stem cell sources ( P = .971 and P = .965). There was no statistical difference in the 5‐year NRM between donor types or stem cell sources ( P = .461 and P = .470).